Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statin therapy and myocardial no-reflow.

J W Calvert1, D J Lefer

  • 1Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

British Journal of Pharmacology
|August 22, 2006
PubMed
Summary

Statins, like simvastatin, offer cardiovascular protection beyond lipid lowering. This study reveals simvastatin activates mitochondrial K(ATP) channels to reduce myocardial no-reflow, a novel cardioprotective mechanism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential importance of alterations in hydrogen sulphide (H2S) bioavailability in diabetes.

British journal of pharmacology·2008
Same author

REVIEW paper: pathophysiology of myocardial reperfusion injury: the role of genetically engineered mouse models.

Veterinary pathology·2008
Same author

Inhibition of c-Jun N-terminal kinase pathway attenuates cerebral vasospasm after experimental subarachnoid hemorrhage through the suppression of apoptosis.

Acta neurochirurgica. Supplement·2008
Same author

Oromandibular reconstruction with vascularized free flaps: a review of 50 cases.

Microsurgery·2004
Same author

Neurovascular protection reduces early brain injury after subarachnoid hemorrhage.

Stroke·2004
Same author

Control of myocardial oxygen consumption in transgenic mice overexpressing vascular eNOS.

American journal of physiology. Heart and circulatory physiology·2004

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Mitochondrial Biology

Background:

  • Statins (HMG-CoA reductase inhibitors) are key in cardiovascular disease treatment.
  • Cardioprotective effects were initially attributed to lipid-lowering, but pleiotropic actions are now recognized.
  • Statins exhibit anti-inflammatory and anti-apoptotic effects, and increase nitric oxide bioavailability.

Purpose of the Study:

  • To elucidate a novel mechanism of statin action in cardiovascular disease.
  • To investigate the effect of simvastatin on myocardial 'no-reflow' following ischemia and reperfusion.
  • To explore the role of mitochondrial K(ATP) channels in statin-mediated cardioprotection.

Main Methods:

  • Experimental models of ischemia and reperfusion injury.
  • Assessment of myocardial 'no-reflow' phenomenon.
  • Pharmacological activation of mitochondrial K(ATP) channels.

Main Results:

  • Simvastatin significantly reduces myocardial 'no-reflow' after ischemia and reperfusion.
  • This protective effect is mediated by the activation of the mitochondrial K(ATP) channel.
  • Identifies a novel, non-lipid-lowering mechanism for statin cardioprotection.

Conclusions:

  • Simvastatin's activation of mitochondrial K(ATP) channels represents a novel cardioprotective mechanism.
  • These findings have significant implications for the therapeutic strategies in cardiovascular diseases.
  • Statins' pleiotropic effects, including channel activation, are crucial for their cardiovascular benefits.

Related Experiment Videos